UnitedHealth Faces DOJ Scrutiny: What’s Happening with Its Stock

UnitedHealth Group (NYSE:UNH) is in the spotlight as the U.S. Department of Justice (DOJ) intensifies its investigation into the company's Medicare Advantage practices. This regulatory pressure and other challenges have caused its shares to drop sharply. Here's what's happening, why it's important, and what investors need to know.

UnitedHealth stock falls amid DOJ Medicare Advantage investigation scrutiny.

Why Is UnitedHealth’s Stock Dropping

UnitedHealth shares fell nearly 4% in premarket trading on July 24, 2025, adding to its nearly 40% decline so far this year, according to analysts. The decline was caused by news that the Justice Department is investigating the company's Medicare business, specifically its Medicare Advantage program, which generated $139 billion in revenue last year. The probe includes both civil and criminal investigations, including concerns about whether UnitedHealth inflated diagnoses to receive higher Medicare payments.

This is not the first hit to 2025's stock. Some reports in May indicated a criminal investigation into potential Medicare fraud, causing the stock price to drop 13%-18%. The ongoing investigation has put investors on edge, as Medicare Advantage is a key part of UnitedHealth’s business.

What’s the Latest on the DOJ Investigation

The Justice Department's healthcare fraud unit has been investigating UnitedHealth since at least last summer, and recent developments have emerged related to interviews with former employees about billing practices. A February 2025 report highlighted a civil fraud investigation, and the latest disclosures confirm that the company is cooperating with both civil and criminal requests. UnitedHealth has disputed the new investigations, denying knowledge of them and calling some of the reports "misinformation." The company says its Medicare Advantage program is run with integrity, but regulatory skepticism still looms.

How Are Other Challenges Impacting UnitedHealth

Aside from the Justice Department investigation, UnitedHealth has had a tough year. Here's a look at some of the challenges:

• Leadership changes: The sudden resignation of CEO Andrew Witty and the assumption of power by Stephen Helmsley in May 2025 raised concerns and added uncertainty.

• Financial struggles: UnitedHealth withdrew a disappointing financial forecast for 2025 after reporting higher-than-expected medical costs in its Medicare Advantage segment. A first-quarter earnings miss, with revenue down $2 billion and earnings per share down $0.09, didn't help either.

• External pressures: A major cyberattack, increased scrutiny on pharmacy benefit managers (PBMs), and the tragic murder of UnitedHealthcare CEO Brian Thompson in December 2024 have further damaged investor confidence.

These factors have pushed UnitedHealth’s stock to a five-year low, with some analysts saying it's trading at a P/E nearly 30% below its five-year average.

Is There a Silver Lining for Investors

Despite the challenges, some analysts see opportunities. The stock's steep decline has left UnitedHealth undervalued, while insider buying has fueled confidence that it can recover. Some reports are giving it a "strong buy" rating, citing the company's leadership in the healthcare sector and long-term growth potential. However, others are warning that regulatory risks and operational issues could delay any recovery, leaving the stock volatile in the near term.

What Are People Saying About UnitedHealth

On platforms like X, the trend is toward pessimism, with some users speculating on hedge fund strategies to drive the stock down. Others are emphasizing legal efforts by UnitedHealth to counter negative coverage, including claims that critical reports threaten to incite violence, including references to the CEO's assassination. These discussions, while vocal, remain speculative and lack verified details.

What Should You Watch Moving Forward

UnitedHealth’s ability to deal with the Justice Department's investigation and stabilize its financial performance will be key. Investors should keep an eye on investigations, quarterly earnings, and any regulatory changes that could impact Medicare Advantage. For real-time stock data and news, platforms like Seeking Alpha or Bloomberg provide reliable information.

This is a developing story, and UnitedHealth’s path forward remains uncertain. Stay tuned for updates as the situation continues to change.